厄洛替尼与化疗治疗晚期非小细胞肺癌的临床观察

目的观察厄洛替尼与含铂化疗方案治疗晚期非小细胞肺癌的疗效和安全性。方法对我院晚期NSCLC给予化疗组30例,服用厄洛替尼组27例定期随访,观察疗效与不良反应。结果 57例可评价疗效的患者中,化疗组30例:CR:0例,PR:6例,SD:10例,PD:14例;缓解率6/30(20%),疾病控制率16/30(53.3%);服用厄洛替尼组27例:CR:2例,PR:8例,SD:14例,PD:3例;缓解率:10/27(37.1%),疾病控制率24/27(88.9%);不良反应主要表现在骨髓抑制、胃肠道反应以及皮疹,发生率在化疗组和厄洛替尼组分别为76.7%、80%、13.3%及3.71%、40.7%、66.7%,三者之间均有显著性差异。结论厄洛替尼治疗晚期NSCLC患者的疗效较化疗组好,且安全性高。

The effects of erlotinib and chemotherapy in the treatment for advanced non-small cell lung cancer

Objective To observe the efficacy and toxicity of chemotherapy and erlotinib in the treatment for advanced non-small cell lung cancer(NSCLC).Methods 57 patients of advanced NSCLC were divided into a platinum-based two agents combination chemotherapy group(30 cases) and erlotinib group(27 cases),and then to study the short-term effectiveness and adverse effects in the two groups.Results Chemotherapy group: Among 30 patients,no one got complete remission,6 patients got partial remission,10 patients were stable and 14 patients developed.The total remission rate was 20%,disease control rate was 53.3%.Erlotinib group: Two patients got complete remission,8 patients got partial remission,14 patients were stable and 3 patients developed.The total remission rate was 37.1%,disease control rate was 88.9%.The major adverse reaction were bone marrow suppression,gastrointestinal reaction and skin rash,the rate were respectively 76.7%,80%,13.3% in chemotherapy group and 3.71%,40.7%,66.7% in erlotinib group.The efficacy between two groups had significant differences.Conclusion Erlotinib is an effective treatment option for advanced NSCLC and with minimal side effects.